Select Clinical Trials announced the launch of its website designed to help identify clinical trials for common illnesses and medical conditions
Select Clinical Trials (SCT) announced the launch of its website designed to help identify clinical trials for common illnesses and medical conditions and provide the public with aneasy-to-use resource to locate clinical studies.
The SCT website contains a directory of available clinical trials, which allows individuals interested in volunteering as trial participants to search based on doctor, therapeutic area, medical condition or zip code. The site provides detailed information about each clinical trial listed such as eligibility criteria, compensation to participants, location, the name of the coordinator and the name of the principal investigator. Clinical trials target both healthy individuals and people living with a specific medical condition. All clinical trials are open to residents of the United States, with age requirements specific to each trial. The new website also features a complete listing of doctors and sites who are currently offering clinical trials. Interested volunteers can research information about the clinical trials before deciding whether to participate. They can also view associated clinical trials and areas of expertise.
Angela Strong, President and CEO of Select Clinical Trials was formerly with Copernicus IRB and Schulman Associates IRB.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.